Sarah K Dotters-Katz1, Marcela C Smid2, Tracy A Manuck1, Torri D Metz3,4. 1. a Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology , University of North Carolina , Chapel Hill , NC , USA. 2. b Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology , University of Utah , Salt Lake City , UT , USA. 3. c Department of Obstetrics and Gynecology , Denver Health Medical Center , Denver , CO , USA. 4. d Department of Obstetrics and Gynecology, University of Colorado School of Medicine , Aurora , CO , USA.
Abstract
BACKGROUND: Limited data exist regarding the neonatal and neurodevelopmental outcomes of infants exposed to marijuana (MJ) in-utero, particularly among preterm infants. We hypothesized that MJ-exposed preterm infants would have worse neonatal and childhood developmental outcomes compared to MJ-unexposed infants. METHODS: Secondary analysis of multicenter randomized-controlled trial of antenatal magnesium sulfate for the prevention of cerebral palsy was conducted. Singleton nonanomalous infants delivered <35 weeks exposed to MJ in-utero were compared to MJ-unexposed. Primary neonatal outcome was death, grade 3/4 intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, and/or stage II/III necrotizing enterocolitis before discharge. Primary childhood outcome was death, moderate/severe cerebral palsy, or/and Bayley II Scales <70 at age 2. Backward-stepwise regression used to estimate odds of primary outcomes. RESULTS:1867 infants met inclusion criteria; 135(7.2%) were MJ-exposed. There were no differences in neonatal (20% vs. 26%, p = 0.14) or childhood (26% vs. 21%, p = 0.21) outcomes in MJ-exposed infants compared to MJ-unexposed infants. In adjusted models, MJ-exposure was not associated with adverse neonatal outcomes (aOR 0.83 95% CI 0.47,1.44) or early childhood outcomes (aOR 1.47, 95% CI 0.97,2.23). CONCLUSIONS: Among infants born <35 weeks of gestation, MJ-exposure was not associated with adverse neonatal or childhood outcomes. Long-term follow-up studies are needed to assess later childhood neurodevelopmental outcomes following MJ-exposure.
RCT Entities:
BACKGROUND: Limited data exist regarding the neonatal and neurodevelopmental outcomes of infants exposed to marijuana (MJ) in-utero, particularly among preterm infants. We hypothesized that MJ-exposed preterm infants would have worse neonatal and childhood developmental outcomes compared to MJ-unexposed infants. METHODS: Secondary analysis of multicenter randomized-controlled trial of antenatal magnesium sulfate for the prevention of cerebral palsy was conducted. Singleton nonanomalous infants delivered <35 weeks exposed to MJ in-utero were compared to MJ-unexposed. Primary neonatal outcome was death, grade 3/4 intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, and/or stage II/III necrotizing enterocolitis before discharge. Primary childhood outcome was death, moderate/severe cerebral palsy, or/and Bayley II Scales <70 at age 2. Backward-stepwise regression used to estimate odds of primary outcomes. RESULTS: 1867 infants met inclusion criteria; 135(7.2%) were MJ-exposed. There were no differences in neonatal (20% vs. 26%, p = 0.14) or childhood (26% vs. 21%, p = 0.21) outcomes in MJ-exposed infants compared to MJ-unexposed infants. In adjusted models, MJ-exposure was not associated with adverse neonatal outcomes (aOR 0.83 95% CI 0.47,1.44) or early childhood outcomes (aOR 1.47, 95% CI 0.97,2.23). CONCLUSIONS: Among infants born <35 weeks of gestation, MJ-exposure was not associated with adverse neonatal or childhood outcomes. Long-term follow-up studies are needed to assess later childhood neurodevelopmental outcomes following MJ-exposure.
Authors: Shayna N Conner; Victoria Bedell; Kim Lipsey; George A Macones; Alison G Cahill; Methodius G Tuuli Journal: Obstet Gynecol Date: 2016-10 Impact factor: 7.661
Authors: Jean Y Ko; Sherry L Farr; Van T Tong; Andreea A Creanga; William M Callaghan Journal: Am J Obstet Gynecol Date: 2015-03-12 Impact factor: 8.661
Authors: Dwight J Rouse; Deborah G Hirtz; Elizabeth Thom; Michael W Varner; Catherine Y Spong; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; James M Alexander; Margaret Harper; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall Carpenter; Menachem Miodovnik; Atef Moawad; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Oded Langer; Steve N Caritis; James M Roberts Journal: N Engl J Med Date: 2008-08-28 Impact factor: 91.245
Authors: Torri D Metz; Amanda A Allshouse; Carol J Hogue; Robert L Goldenberg; Donald J Dudley; Michael W Varner; Deborah L Conway; George R Saade; Robert M Silver Journal: Am J Obstet Gynecol Date: 2017-05-31 Impact factor: 8.661
Authors: Marcela C Smid; Torri D Metz; Gwen A McMillin; Lisa Mele; Brian M Casey; Uma M Reddy; Ronald J Wapner; John M Thorp; George R Saade; Alan T N Tita; Emily S Miller; Dwight J Rouse; Baha Sibai; Maged M Costantine; Brian M Mercer; Steve N Caritis Journal: Obstet Gynecol Date: 2022-01-01 Impact factor: 7.623
Authors: Lynn M Yee; Deborah Kacanek; Chase Brightwell; Lisa B Haddad; Jennifer Jao; Kathleen M Powis; Tzy-Jyun Yao; Emily Barr; Carly Broadwell; Suzanne Siminski; George R Seage; Ellen G Chadwick Journal: JAMA Netw Open Date: 2021-12-01